Latest news with #ducts
The Advertiser
3 days ago
- Automotive
- The Advertiser
Genesis GV60 Magma spied: Heated up electric SUV takes shape
Genesis is about to launch its Magma performance sub-brand, and the first cab off the rank is a hotted up version of the GV60 small electric SUV. Spotted outside the Nurburgring in Germany, this prototype has a new, more aggressive front fascia with larger air intakes and sculpted surrounds that look very similar to the front clip of the 2024 GV60 Magma concept car. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The Magma's tracks might be a little wider than other GV60 variants, but the hulking wheel-arch extensions of the concept are nowhere to be seen on the prototype. That said, there seem to be little ducts tucked into the trailing edge of the front wheel-arches. At the back the Magma has a larger-than-regular spoiler at the base of the windscreen but, again, it's nowhere near as wild as the unit fitted to last year's concept car. Drivetrain details have yet to be revealed, but it's possible the GV60 Magma will share a lot in common with the Hyundai Ioniq 5 N as both cars rides on the Korean automaker's e-GMP architecture. The Ioniq 5 N has a dual-motor all-wheel drive system making a total of 478kW of power and 770Nm of torque It is capable of completing the 0-100km/h dash in a claimed 3.4 seconds, and driven more sedately the 84kWh battery pack provides a driving range of 448km according to the WLTP standard. Currently the most powerful variant of the GV60 range boasts 360kW and 700Nm. With the GV60 Magma set to launch in South Korea from the fourth quarter of this year, we won't have to wait too long to find out the details. According to Mike Song, global chief of the Genesis brand, it should arrive in Australia from the first quarter of 2026. The rest of the Genesis range will also gain Magma variants, all of which will arrive in Australia at some stage, with the exception of the flagship G90 sedan, which isn't available in right-hand drive. So far Genesis has revealed Magma concept versions of the GV80 large SUV and G80 large sedan. MORE: Everything Genesis GV60 Content originally sourced from: Genesis is about to launch its Magma performance sub-brand, and the first cab off the rank is a hotted up version of the GV60 small electric SUV. Spotted outside the Nurburgring in Germany, this prototype has a new, more aggressive front fascia with larger air intakes and sculpted surrounds that look very similar to the front clip of the 2024 GV60 Magma concept car. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The Magma's tracks might be a little wider than other GV60 variants, but the hulking wheel-arch extensions of the concept are nowhere to be seen on the prototype. That said, there seem to be little ducts tucked into the trailing edge of the front wheel-arches. At the back the Magma has a larger-than-regular spoiler at the base of the windscreen but, again, it's nowhere near as wild as the unit fitted to last year's concept car. Drivetrain details have yet to be revealed, but it's possible the GV60 Magma will share a lot in common with the Hyundai Ioniq 5 N as both cars rides on the Korean automaker's e-GMP architecture. The Ioniq 5 N has a dual-motor all-wheel drive system making a total of 478kW of power and 770Nm of torque It is capable of completing the 0-100km/h dash in a claimed 3.4 seconds, and driven more sedately the 84kWh battery pack provides a driving range of 448km according to the WLTP standard. Currently the most powerful variant of the GV60 range boasts 360kW and 700Nm. With the GV60 Magma set to launch in South Korea from the fourth quarter of this year, we won't have to wait too long to find out the details. According to Mike Song, global chief of the Genesis brand, it should arrive in Australia from the first quarter of 2026. The rest of the Genesis range will also gain Magma variants, all of which will arrive in Australia at some stage, with the exception of the flagship G90 sedan, which isn't available in right-hand drive. So far Genesis has revealed Magma concept versions of the GV80 large SUV and G80 large sedan. MORE: Everything Genesis GV60 Content originally sourced from: Genesis is about to launch its Magma performance sub-brand, and the first cab off the rank is a hotted up version of the GV60 small electric SUV. Spotted outside the Nurburgring in Germany, this prototype has a new, more aggressive front fascia with larger air intakes and sculpted surrounds that look very similar to the front clip of the 2024 GV60 Magma concept car. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The Magma's tracks might be a little wider than other GV60 variants, but the hulking wheel-arch extensions of the concept are nowhere to be seen on the prototype. That said, there seem to be little ducts tucked into the trailing edge of the front wheel-arches. At the back the Magma has a larger-than-regular spoiler at the base of the windscreen but, again, it's nowhere near as wild as the unit fitted to last year's concept car. Drivetrain details have yet to be revealed, but it's possible the GV60 Magma will share a lot in common with the Hyundai Ioniq 5 N as both cars rides on the Korean automaker's e-GMP architecture. The Ioniq 5 N has a dual-motor all-wheel drive system making a total of 478kW of power and 770Nm of torque It is capable of completing the 0-100km/h dash in a claimed 3.4 seconds, and driven more sedately the 84kWh battery pack provides a driving range of 448km according to the WLTP standard. Currently the most powerful variant of the GV60 range boasts 360kW and 700Nm. With the GV60 Magma set to launch in South Korea from the fourth quarter of this year, we won't have to wait too long to find out the details. According to Mike Song, global chief of the Genesis brand, it should arrive in Australia from the first quarter of 2026. The rest of the Genesis range will also gain Magma variants, all of which will arrive in Australia at some stage, with the exception of the flagship G90 sedan, which isn't available in right-hand drive. So far Genesis has revealed Magma concept versions of the GV80 large SUV and G80 large sedan. MORE: Everything Genesis GV60 Content originally sourced from: Genesis is about to launch its Magma performance sub-brand, and the first cab off the rank is a hotted up version of the GV60 small electric SUV. Spotted outside the Nurburgring in Germany, this prototype has a new, more aggressive front fascia with larger air intakes and sculpted surrounds that look very similar to the front clip of the 2024 GV60 Magma concept car. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The Magma's tracks might be a little wider than other GV60 variants, but the hulking wheel-arch extensions of the concept are nowhere to be seen on the prototype. That said, there seem to be little ducts tucked into the trailing edge of the front wheel-arches. At the back the Magma has a larger-than-regular spoiler at the base of the windscreen but, again, it's nowhere near as wild as the unit fitted to last year's concept car. Drivetrain details have yet to be revealed, but it's possible the GV60 Magma will share a lot in common with the Hyundai Ioniq 5 N as both cars rides on the Korean automaker's e-GMP architecture. The Ioniq 5 N has a dual-motor all-wheel drive system making a total of 478kW of power and 770Nm of torque It is capable of completing the 0-100km/h dash in a claimed 3.4 seconds, and driven more sedately the 84kWh battery pack provides a driving range of 448km according to the WLTP standard. Currently the most powerful variant of the GV60 range boasts 360kW and 700Nm. With the GV60 Magma set to launch in South Korea from the fourth quarter of this year, we won't have to wait too long to find out the details. According to Mike Song, global chief of the Genesis brand, it should arrive in Australia from the first quarter of 2026. The rest of the Genesis range will also gain Magma variants, all of which will arrive in Australia at some stage, with the exception of the flagship G90 sedan, which isn't available in right-hand drive. So far Genesis has revealed Magma concept versions of the GV80 large SUV and G80 large sedan. MORE: Everything Genesis GV60 Content originally sourced from:
7NEWS
3 days ago
- Automotive
- 7NEWS
Genesis GV60 Magma spied: Heated up electric SUV takes shape
Genesis is about to launch its Magma performance sub-brand, and the first cab off the rank is a hotted up version of the GV60 small electric SUV. Spotted outside the Nurburgring in Germany, this prototype has a new, more aggressive front fascia with larger air intakes and sculpted surrounds that look very similar to the front clip of the 2024 GV60 Magma concept car. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. The Magma's tracks might be a little wider than other GV60 variants, but the hulking wheel-arch extensions of the concept are nowhere to be seen on the prototype. That said, there seem to be little ducts tucked into the trailing edge of the front wheel-arches. At the back the Magma has a larger-than-regular spoiler at the base of the windscreen but, again, it's nowhere near as wild as the unit fitted to last year's concept car. Drivetrain details have yet to be revealed, but it's possible the GV60 Magma will share a lot in common with the Hyundai Ioniq 5 N as both cars rides on the Korean automaker's e-GMP architecture. The Ioniq 5 N has a dual-motor all-wheel drive system making a total of 478kW of power and 770Nm of torque It is capable of completing the 0-100km/h dash in a claimed 3.4 seconds, and driven more sedately the 84kWh battery pack provides a driving range of 448km according to the WLTP standard. Currently the most powerful variant of the GV60 range boasts 360kW and 700Nm. With the GV60 Magma set to launch in South Korea from the fourth quarter of this year, we won't have to wait too long to find out the details. According to Mike Song, global chief of the Genesis brand, it should arrive in Australia from the first quarter of 2026. The rest of the Genesis range will also gain Magma variants, all of which will arrive in Australia at some stage, with the exception of the flagship G90 sedan, which isn't available in right-hand drive. So far Genesis has revealed Magma concept versions of the GV80 large SUV and G80 large sedan.
Perth Now
3 days ago
- Automotive
- Perth Now
Genesis GV60 Magma spied: Heated up electric SUV takes shape
Genesis is about to launch its Magma performance sub-brand, and the first cab off the rank is a hotted up version of the GV60 small electric SUV. Spotted outside the Nurburgring in Germany, this prototype has a new, more aggressive front fascia with larger air intakes and sculpted surrounds that look very similar to the front clip of the 2024 GV60 Magma concept car. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. Supplied Credit: CarExpert The Magma's tracks might be a little wider than other GV60 variants, but the hulking wheel-arch extensions of the concept are nowhere to be seen on the prototype. That said, there seem to be little ducts tucked into the trailing edge of the front wheel-arches. At the back the Magma has a larger-than-regular spoiler at the base of the windscreen but, again, it's nowhere near as wild as the unit fitted to last year's concept car. Drivetrain details have yet to be revealed, but it's possible the GV60 Magma will share a lot in common with the Hyundai Ioniq 5 N as both cars rides on the Korean automaker's e-GMP architecture. Supplied Credit: CarExpert The Ioniq 5 N has a dual-motor all-wheel drive system making a total of 478kW of power and 770Nm of torque It is capable of completing the 0-100km/h dash in a claimed 3.4 seconds, and driven more sedately the 84kWh battery pack provides a driving range of 448km according to the WLTP standard. Currently the most powerful variant of the GV60 range boasts 360kW and 700Nm. With the GV60 Magma set to launch in South Korea from the fourth quarter of this year, we won't have to wait too long to find out the details. According to Mike Song, global chief of the Genesis brand, it should arrive in Australia from the first quarter of 2026. Supplied Credit: CarExpert The rest of the Genesis range will also gain Magma variants, all of which will arrive in Australia at some stage, with the exception of the flagship G90 sedan, which isn't available in right-hand drive. So far Genesis has revealed Magma concept versions of the GV80 large SUV and G80 large sedan. MORE: Everything Genesis GV60
Daily Mirror
21-05-2025
- Health
- Daily Mirror
Women with these type of breasts could have cancer missed by routine NHS scans
Women with dense breast tissue could soon be offered extra scans on the NHS after Lancet study shows cancers can remain "hidden" during regular mammograms Better breast cancer screening could identify 3,500 more cancerous lumps every year and save hundreds of lives, research shows. A new study in the Lancet has shown that two extra scans for women with dense breasts can pick up early-stage cancers that remain "hidden" during regular mammograms. Cambridge University scientists say these additional scans - which make blood vessels more visible during mammograms - should be offered as they would more than treble cancer detection. Around 10% of women have very dense breasts, which means they have more fibrous and glandular tissue and less fatty tissue. Study lead Professor Fiona Gilbert, of Cambridge University and honorary consultant radiologist at Addenbrooke's Hospital, said: "Getting a cancer diagnosis early makes a huge difference for patients in terms of their treatment and outlook. "We need to change our national screening programme so we can make sure more cancers are diagnosed early, giving many more women a much better chance of survival." Those with dense breasts are already known to face a four-fold increased risk of breast cancer compared to women without. At the moment denser breasts look whiter on mammograms so standard scans cannot pick up all cancers. Early-stage cancers also appear white, meaning they are difficult to distinguish. The BRAID trial was carried out on 9,361 women across the UK who have dense breasts and had a negative mammogram result. When additional scanning methods were offered an extra 85 cancers were found. The UK National Screening Committee is reviewing this evidence and it could result in woman with dense breast tissue being offered extra scans on the NHS. Louise's Story Louise Duffield, age 60, was diagnosed with early-stage breast cancer as a result of the trial. The grandmother-of-four was invited to participate in 2023 following her regular mammogram screening, which showed that she had very dense breasts. As part of the trial, Louise had an AB-MRI scan which identified a small lump deep inside one of her breasts. Louise, from Ely, in Cambridgeshire, said: 'When they rang to say they'd found something, it was a big shock. You start thinking all sorts of things but, in the end, I just thought, at least if they've found something, they've found it early. The staff were brilliant, and so supportive.' Soon after the MRI, Louise had a biopsy that confirmed she had stage 0 - very early - breast cancer within the ducts of one of her breasts. Six weeks later Louise underwent surgery to remove the tumour, during that time the tumour had already grown larger than it appeared on the scans. The location of Louise's tumour meant it would have been difficult for her to find it through self-examination, and since it was not detected during her regular mammogram it would have been at least three years before she was invited for another. Louise said: 'It's been a stressful time and it's a huge relief to have it gone. The team have been fantastic throughout. The tumour was deep in the breast so, if I hadn't been on the trial, it could have gone unnoticed for years. I feel very lucky, it almost doesn't feel like I've really had cancer. Without this research I could have had a very different experience.' The two extra scanning methods examined in the trial were contrast enhanced mammography (CEM), where dye is used to make blood vessels more visible, and abbreviated magnetic resonance imaging (AB-MRI), which is faster than a regular MRI. The experts calculated that adding either of these methods to existing breast screening could detect 3,500 more cancers per year in the UK. Researchers said that because screening reduces death for about 20% of cancers detected and this could mean an extra 700 lives saved each year. Leading screening expert Professor Stephen Duffy, from Queen Mary University, London, said: "The NHS breast screening programme has made a huge difference to many lives. Thanks to these results, we can see that the technology exists to make screening even better, particularly for the 10% of women with dense breast tissue." Dr David Crosby, head of prevention and early detection at Cancer Research UK, said: "This study shows that making blood vessels more visible during mammograms could make it much easier for doctors to spot signs of cancer in women with dense breasts. More research is needed to fully understand the effectiveness of these techniques, but these results are encouraging." A third scanning method used in the trial - automated whole breast ultrasound (ABUS) - also picked up cancers but was much less effective than CEM and AB-MRI. Overall, per 1,000 women scanned, CEM detected 19 cancers, while AB-MRI found 17 and ABUS found four. With mammograms already detecting around eight cancers per 1,000 women with dense breasts, additional scans could therefore more than treble breast cancer detection. The trial was funded by Cancer Research UK with support from the National Institute for Health and Care Research Cambridge Biomedical Research Centre. Dr Kotryna Temcinaite, of charity Breast Cancer Now, said: "The UK National Screening Committee now needs to consider this research as part of their current review to determine whether women with very dense breasts should be offered additional imaging during their routine screening. If the UK National Screening Committee recommends additional imaging for screening women with very dense breasts, we'll push for those changes to be rolled out as quickly as possible across the UK. "Routine breast screening is the most likely route to finding breast cancer early, when treatment is most likely to be successful. While we know that the current process can be less effective in detecting cancers in dense breasts, we still encourage all women to attend mammogram screening when invited." A Department for Health and Social Care spokesperson said: "Research is being conducted into the use of additional tests for women with dense breasts, as part of the NHS breast screening programme. The UK National Screening Committee is reviewing this evidence as it becomes available."
Yahoo
27-01-2025
- Business
- Yahoo
Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board
Scientific Advisory Board formed with internationally recognized liver and biliary tract cancer physicians to support the advancement of solid tumor pipeline programs Elevar plans for major 2025 oncology regulatory milestones- March 2025 PDUFA date and launch preparation for unresectable hepatocellular carcinoma- NDA Submission for lirafugratinib in second half 2025 for FGFR2 driven cholangiocarcinoma FORT LEE, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a portfolio company of HLB Co., Ltd., today announced the formation of its Scientific Advisory Board (SAB) with internationally renowned experts in the discovery and development of next generation hepatocellular carcinoma and cholangiocarcinoma cancer therapies. 'We proudly welcome our newly formed Scientific Advisory Board, a distinguished group of oncology clinicians who will play a crucial role in supporting our research and development strategy. Their individual and collective expertise will be invaluable as we strive to make a meaningful impact in the fight against cancer,' commented Chris Galloway, M.D., senior vice president of clinical development and medical affairs at Elevar. Mitesh Borad, M.D. Mitesh J. Borad, M.D., is the Getz Family Research Professor and leads the Novel Therapeutics and Modalities Program at Mayo Clinic. Dr. Borad is an internationally recognized expert for treating patients with cholangiocarcinoma and has been extensively involved in developing novel cancer therapeutic platforms that leverage genomic medicine and gene/virus therapies, with a focus on tumors of the liver, bile ducts and pancreas. He has led the clinical development of novel anti-cancer agents in more than 50 first-in-human studies, including a multi-institutional team with collaborators at Mayo Clinic and the Translational Genomics Research Institute, which led to the discovery of fibroblast growth factor 2 (FGFR2) fusions in patients with intrahepatic cholangiocarcinoma, with the first demonstration of anti-tumor activity with FGFR inhibitors in this patient population. Subsequent work led to the FDA approval of three FGFR inhibitor cancer therapies. Richard Kim, M.D. Dr. Richard Kim is a Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center and a Professor of Oncology at the University of South Florida College of Medicine. Before joining Moffitt in 2010, Dr. Kim was an associate physician in gastrointestinal malignancies at the Cleveland Clinic Taussig Cancer Center and a clinical assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, OH. Dr. Kim's clinical and research interests focus on gastrointestinal tumors, in particular hepatobiliary and colon cancer. He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I, II and III trials using immunotherapy and novel targeted agents. Daneng Li, M.D. Daneng Li, M.D. is an Associate Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li's clinical and academic research is focused on the multidisciplinary approach to treatment of patients with neuroendocrine tumors (NETs). He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Rachna T Shroff, M.D., M.S. Rachna T. Shroff, MD, MS, FASCO, serves as associate director of Clinical Investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC) and is a professor in the Department of Medicine, chief of the Division of Hematology and Oncology, medical director for the Oncology Service Line and associate dean for Clinical and Translational Research for the University of Arizona College of Medicine – Tucson. Dr. Shroff joined UACC from MD Anderson Cancer Center in Houston. She is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers and has led numerous clinical trials focusing on pancreaticobiliary tumors. She was the national principal investigator for SWOG 1815, which investigated a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. About Elevar Therapeutics Elevar Therapeutics, Inc., a fully owned subsidiary of HLB Group, is a fully integrated biopharmaceutical company built on the promise of elevating treatment outcomes for patients who have limited or inadequate therapeutic options. With expertise rooted in oncology, Elevar is focused on identifying and developing promising medicines for complex yet under-treated health conditions. Elevar's lead proprietary drug candidate is rivoceranib. The NDA for rivoceranib in combination with camrelizumab as a therapy for advanced or metastatic hepatocellular carcinoma (HCC) is currently under review by the FDA with a PDUFA action date scheduled for March 20, 2025. On December 2, 2023, Elevar acquired worldwide rights to develop and commercialize lirafugratinib (RLY-4008), an FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma (CCA) and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors. An NDA submission for lirafugratinib is planned for 2025. Additional information is available at About HLB Group The HLB Group is comprised of HLB Inc. (KOSDAQ:028300) and its affiliates with a diverse portfolio across biopharma, lifestyle, marine business, semiconductor and energy, united by the mission of improving all aspects of human life. Members of the HLB Group include HLB Innovation (KOSDAQ: 024850), HLB BioStep (KOSDAQ:278650), HLB Pharmaceutical (KOSDAQ:047920), HLB Life Science (KOSDAQ:067630), HLB Therapeutics (KOSDAQ:115450), HLB Panagene (KOSDAQ:046210) and HLB Global (KOSDAQ:003580). HLB Group's overseas affiliates include Elevar Therapeutics, Immunomic Therapeutics, a nucleic acid immunotherapy platform company, and Verismo Therapeutics, a CAR T platform oncology company, and a fully owned subsidiary of HLB Innovation, both based in the United States. Contacts Media: Jeanette BressiHead, Corporate Communications jbressi@ 609-439-3997 Investors: Wade SmithChief Financial & Business Officer wsmith@
